Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient herbal remedy put to the test for asthma relief

NCT ID NCT07352488

Disease control Sponsor: Henan University of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a traditional Chinese medicine powder called Modified Shenling Baizhu Powder to standard asthma inhalers can improve symptom control in people with allergic asthma. Researchers will enroll 400 adults aged 18 to 80 who have persistent asthma and a specific traditional Chinese medicine diagnosis. Participants will take either the herbal powder or a placebo twice daily for 8 weeks, alongside their usual inhaler, and be followed for 12 more weeks to track asthma control, flare-ups, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Modified Shenling Baizhu Powder (traditional Chinese herbal powder)
What this could lead to
If it works, this could provide an additional treatment option to help control allergic asthma symptoms and reduce flare-ups.
What could go wrong
This is an early-stage trial with no phase specified, so results are uncertain. The herbal powder may not provide added benefit over standard inhalers, and side effects are not yet well understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are persistent allergic asthma. * Patients who meet the diagnostic criteria for the spleen deficiency and dampness accumulation syndrome. * Patients who are aged between 18 and 80 years. * Patients who voluntarily accept the treatment and sign the informed consent form. Exclusion Criteria: * Patients who have chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis , active pulmonary tuberculosis, or pulmonary embolism, etc. * Patients who have severe cardiovascular or cerebrovascular diseases. * Patients who have severe liver or kidney diseases. * Patients who have a history of tumor. * Patients who have cognitive impairment or psychiatric disorders. * Patients who are pregnant or breastfeeding. * Patients who are allergic to medication(s) used. * Patients who participated in another clinical trial within one month prior to enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Shandong University of Traditional Chinese Medicine

    Jinan, Shandong, 250011, China

  • Hangzhou Third People's Hospital

    Hangzhou, Zhejiang, 310009, China

  • The First Affiliated Hospital of Henan University of Chinese Medicine

    Zhengzhou, Henan, 450003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.